Moleculin Annamycin outperforms control in pivotal AML trial

Moleculin reported positive interim results from its MIRACLE trial, showing Annamycin achieved three-fold higher complete remission rates than the control. Strong efficacy in a difficult patient population supports the company's path toward regulatory approval.